Recent Updates
Recently added Catalysts
NTRA Positive Sentiment

Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Natera, Inc. announced new data on Signatera at the SITC Annual Meeting. The study indicates that clearance of circulating tumor DNA (ctDNA) during first-line immunotherapy correlates with long-term survival in patients with metastatic cancers. This finding could enhance monitoring strategies for patients undergoing treatment with immune checkpoint inhibitors.

Market Sentiment Analysis

POSITIVE FACTORS

  • New data shows ctDNA clearance linked to long-term survival.
  • Signatera data presented at a prominent cancer meeting.
  • Potential for improved patient monitoring during immunotherapy.

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present important new Signatera data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 4–8 in Phoenix, Arizona. Immune checkpoint inhibitors (ICIs) have transformed treatment for many metastatic cancers, and some patients achieve durable disease control.1 However, it remains challenging for clinicians to determine how

Frequently Asked Questions

What is Signatera?

Signatera is a personalized ctDNA test developed by Natera for cancer monitoring.

What was presented at the SITC Annual Meeting?

Natera presented data linking ctDNA clearance to long-term survival in metastatic cancers.

How does ctDNA relate to cancer treatment?

ctDNA clearance during treatment may indicate better patient outcomes and survival.

What are immune checkpoint inhibitors?

ICIs are therapies that help the immune system recognize and attack cancer cells.

ShareAdd on Google
Tags: NTRA Natera Signatera ctDNA immunotherapy metastatic cancer
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$1092M liquidity · $0M/mo burn
Low dilution risk